Multiple Sclerosis (MS) Primary Progressive
11
5
5
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
9%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (11)
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis
Acute Intermittent Hypoxia Combined With Gait Training in Multiple Sclerosis
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Home Based Functional Balance Intervention for Multiple Sclerosis
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography